Lasa Supergeneri

Lasa-Supergenerics-Ltd29 Apr 2024

Pharmaceuticals

₹

+0.05 (+0.20%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Lasa Supergeneri

Lasa Supergeneri

Pharmaceuticals

Lasa-Supergenerics-Ltd29 Apr 2024

₹

+0.05 (+0.20%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
11-Apr-2022	D	Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 10.30 a.m. and concluded at 12:45 p.m. inter- alia have considered and approved the following: 1. Recommendation of the final Dividend of Rs 0.25 (2.5%) per equity share for the financial year ended March 31, 2022, subject to the approval of the shareholders at the ensuing General Meeting of the Company.	16-Sep-2022
31-May-2021	D	Lasa Supergenerics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 31, 2021, inter alia, has recommendationof the final Dividend of Rs. 0.25 (2.5%) per equity share for the financial year ended March 31, 2021, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.	15-Sep-2021
26-Apr-2024	BC	Mr.Ravi Shankar kabra, CFO of the company tendered his resignation vide letter dated April 25,2024 due to health reasons and other pre occupations, he will be relieved of his duties effective end of	26-Apr-2024
08-Mar-2024	BC	Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com	08-Mar-2024
08-Mar-2024	BC	Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com	08-Mar-2024
05-Feb-2024	BC	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securit	13-Feb-2024
04-Nov-2023	BC	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securit	10-Nov-2023

No Rights has been declared by Lasa-Supergenerics-Ltd

Book Closure

Record Date	Split Date	Purpose
26-Apr-2024	-	Mr.Ravi Shankar kabra, CFO of the company tendered his resignation vide letter dated April 25,2024 due to health reasons and other pre occupations, he will be relieved of his duties effective end of
08-Mar-2024	-	Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com
08-Mar-2024	-	Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com
13-Feb-2024	-	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securit
10-Nov-2023	-	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securit

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Lasa Supergenerics Ltd ₹25.60(+0.05/0.20%)	25.60	+0.05	128.26	5.14	0.00	1.13
Lupin Ltd ₹1,637.45(+21.50/1.33%)	1,637.45	+21.50	74,626.80	128.34	36.21	3.87
Ipca Laboratories Ltd ₹1,334.00(-4.50/-0.34%)	1,334.00	-4.50	33,844.14	90.83	61.44	5.45
J B Chemicals & Pharmaceuticals Ltd ₹1,906.65(+41.60/2.23%)	1,906.65	+41.60	29,590.22	77.48	58.44	11.03
Sanofi India Ltd ₹8,277.50(+3.35/0.04%)	8,277.50	+3.35	19,063.08	38.57	32.30	18.78
IOL Chemicals & Pharmaceuticals Ltd ₹396.50(-3.00/-0.75%)	396.50	-3.00	2,327.67	-2.77	13.49	1.46

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	26.66	24.30	30.56	35.32	31.70	33.66
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	26.66	24.30	30.56	35.32	31.70	33.66
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.00	0.08	0.00	0.93	0.86	0.00
Total Income	26.66	24.39	30.56	36.25	32.57	33.67
Total Expenditure	25.61	23.26	26.51	50.88	34.17	36.47
PBIDT	1.06	1.13	4.05	-14.63	-1.60	-2.80
Interest	0.44	0.56	0.37	0.41	0.43	0.84
PBDT	0.62	0.57	3.68	-15.04	-2.03	-3.64
Depreciation	2.68	2.68	2.65	4.17	3.09	3.09
Tax	0.00	0.00	0.00	0.00	0.00	0.04
Deferred Tax	-0.61	-2.09	5.98	-4.21	-0.20	-0.18
Reported Profit After Tax	-1.46	-0.02	-4.95	-15.00	-4.92	-6.61
Extra-ordinary Items	0.00	0.00	0.00	-19.90	0.00	-2.45
Adjusted Profit After Extra-ordinary item	-1.46	-0.02	-4.95	4.90	-4.92	-4.16

EPS (Unit Curr.)	-0.29	0.00	-0.99	-2.99	-1.21	-1.62
EPS (Adj) (Unit Curr.)	-0.29	0.00	-0.99	-2.99	-1.21	-1.62
Calculated EPS (Unit Curr.)	-0.29	0.00	-0.99	-2.99	-0.98	-1.62
Calculated EPS (Adj) (Unit Curr.)	-0.29	0.00	-0.99	-2.99	-0.98	-1.62
Calculated EPS (Ann.) (Unit Curr.)	-1.16	-0.02	-3.95	-11.98	-3.93	-6.50
Calculated EPS (Adj) (Ann.) (Unit Curr.)	-1.16	-0.02	-3.95	-11.98	-3.93	-6.50
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	50.10	50.10	50.10	50.10	50.10	40.67
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	3.98	4.65	13.25	-41.42	-5.05	-8.32
PBDTM(%)	2.33	2.35	12.04	-42.58	-6.40	-10.81
PATM(%)	-5.48	-0.08	-16.20	-42.47	-15.52	-19.64

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	50.10	50.10	40.67	40.67	22.86	22.86
Reserves Total	68.18	107.78	118.24	100.79	82.43	94.48
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	118.28	157.88	158.91	141.46	105.29	117.34
Secured Loans	0.00	0.00	0.00	34.04	39.03	45.82
Unsecured Loans	21.77	20.17	19.46	14.37	45.57	60.84
Total Debt	21.77	20.17	19.46	48.41	84.60	106.66
Total Liabilities	140.05	178.05	178.37	189.87	189.89	224.00
APPLICATION OF FUNDS :
Gross Block	228.70	233.77	226.12	219.54	211.87	200.58
Less : Accumulated Depreciation	109.74	96.49	83.17	67.35	50.17	30.94
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	118.96	137.28	142.95	152.19	161.70	169.64
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	4.64	4.58	0.00	0.00	7.21	7.24
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.39	0.38	0.00	0.00	0.00	0.00
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	13.90	11.50	17.26	26.30	31.60	42.23
Sundry Debtors	2.48	18.56	14.77	20.65	28.88	42.15
Cash and Bank	2.39	17.22	4.40	6.06	2.69	2.63
Loans and Advances	20.45	19.02	27.90	22.86	22.67	22.16
Total Current Assets	39.22	66.30	64.32	75.88	85.83	109.18
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	10.82	18.56	14.74	36.68	65.75	56.65
Provisions	10.14	6.02	6.34	4.97	2.49	4.23
Total Current Liabilities	20.96	24.58	21.07	41.65	68.24	60.88
Net Current Assets	18.26	41.72	43.25	34.23	17.59	48.30
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.34	0.32	0.00	15.90	17.21	16.72
Deferred Tax Liability	2.57	6.23	7.82	12.73	14.19	18.38
Net Deferred Tax	-2.23	-5.91	-7.82	3.17	3.02	-1.66
Total Assets	140.02	178.04	178.38	189.59	189.51	223.52
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	11.07	4.81	2.57	0.42	0.50
Net Cash from Operating Activities	-17.30	9.21	41.31	13.62	40.66
Net Cash Used In Investing Activities	11.19	-2.91	-3.60	-1.63	-7.34
Net Cash Used In Financing Activities	-4.16	-0.04	-36.44	-9.85	-33.40
Net Inc./Dec In Cash And Cash Equivalents	-10.27	6.26	1.27	2.15	-0.08
Cash And Cash Equivalents At End Of The Year	0.80	11.07	3.84	2.57	0.42

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

53.65%

FII Shareholding

0.12%

DII Shareholding

0.00%

Public Shareholding

46.23%

**Promoter pledged shareholding 53.65%

About Lasa Supergenerics Ltd

Lasa Supergenerics Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 128.41 crores. It has reported a sales of Rs. 26.66 crores and a net profit of Rs. -1.46 crores for the quarter ended December 2018. The company management includes Omkar P Herlekar, Omkar P Herlekar,Shivanand Hedge,Hardesh Tolani,Ajay Sukhwani,Ekta Gurnasinghani,Mitti M Jain,Manali Bhagtani (Lasa Supergenerics Ltd) among others.

Chairman

Omkar P Herlekar

Registered office

C-105 MIDC,Mahad,Raigad,Maharashtra,402301

FAX :

Background

Incorporation Year2016

Face Value₹10

Market Lot1

How to buy Lasa Supergeneri shares on nse?

To buy Lasa Supergeneri shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Lasa Supergeneri share price today?

The Lasa Supergeneri shares price on nse is Rs.25.6 today.

What is the market cap of Lasa Supergeneri shares on NSE ?

The company has a market capitalization of Rs.128.26Cr

What is the PE & PB ratio of Lasa Supergeneri shares ?

PE is 0 and PB is 1.13

What is the 52 Week High and Low of Lasa Supergeneri shares?

Lasa Supergeneri stock price high: Rs.41.2 Lasa Supergeneri stock price low: Rs.20.6